Once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) therapy has moved into a new phase with FDA approval of LIB Therapeutics’ Lerochol for adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). The approval highlights a clear industry shift toward long-acting, adherence-focused lipid-lowering options as payers, clinicians, and innovators prioritize sustained LDL-C control in high-risk cardiovascular populations, says GlobalData, a leading intelligence and productivity platform.

The approval is based on results from the Phase III LIBerate program, which enrolled over 2,900 high‑risk patients, such as those with established cardiovascular disease and HeFH. In the pivotal LIBerate‑004 study, once‑monthly Lerochol reduced low-density lipoprotein cholesterol (LDL‑C) by about 60% versus placebo and enabled nearly 70% of HeFH patients to reach guideline LDL‑C targets.

Lerochol, which is expected to be launched in the US in spring 2026, also lowered apolipoprotein B by about 50% and lipoprotein(a) by about 25%, was generally well tolerated, and showed no treatment‑related serious adverse events, with injection‑site reactions the main reason for discontinuation.

Dr Shireen Mohammad, Senior Cardiovascular & Metabolic Disorders Analyst at GlobalData, comments: “Lerochol, like established PCSK9 inhibitors such as Regeneron’s Praluent (alirocumab) and Amgen’s Repatha (evolocumab), targets the PCSK9 protein to help reduce LDL-C levels. However, it distinguishes itself with its unique design as a long-acting bispecific monoclonal antibody, which may provide an added advantage over existing treatments for dyslipidemia. Lerochol offers the convenience of a once-monthly injection, reducing the dosing frequency compared to many other PCSK9 inhibitors.”

The key opinion leaders (KOLs) interviewed by GlobalData have noted that patients often prefer a once-monthly injection over daily pills, as it is more convenient and reduces the burden of daily medication, potentially improving adherence for life-long therapy needed in HeFH.

Dr Mohammad concludes: “Despite current treatments with statins, ezetimibe, and existing PCSK9 inhibitors, many patients with HeFH or very high cardiovascular risk still do not meet LDL-C goals. The approval of Lerochol expands the PCSK9 inhibitor class and provides an additional option for patients who need more intensive LDL-C lowering or remain insufficiently controlled on current therapies.”